It has been suggested that recurrent tumors may acquire extra mutations and evolve along two distinct molecular pathways governed by p53 mutation (Type 1 GBM) or EGFR amplification (Type 2 GBM) (51). This evidence concerns the gene TP53 and glioblastoma.